Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

SEHK:6990 Stock Report

Market Cap: HK$39.8b

Sichuan Kelun-Biotech Biopharmaceutical Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Junyou Ge

Chief executive officer

CN¥17.9m

Total compensation

CEO salary percentage14.3%
CEO tenure3.8yrs
CEO ownershipn/a
Management average tenure3.3yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 21
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth

Jun 14
We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth

Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results

Mar 27
Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results

An Intrinsic Calculation For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Suggests It's 45% Undervalued

Jan 11
An Intrinsic Calculation For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Suggests It's 45% Undervalued

CEO Compensation Analysis

How has Junyou Ge's remuneration changed compared to Sichuan Kelun-Biotech Biopharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥187m

Mar 31 2024n/an/a

-CN¥354m

Dec 31 2023CN¥18mCN¥3m

-CN¥522m

Sep 30 2023n/an/a

-CN¥427m

Jun 30 2023n/an/a

-CN¥333m

Mar 31 2023n/an/a

-CN¥440m

Dec 31 2022CN¥3mCN¥2m

-CN¥548m

Compensation vs Market: Junyou's total compensation ($USD2.46M) is above average for companies of similar size in the Hong Kong market ($USD788.79K).

Compensation vs Earnings: Junyou's compensation has increased whilst the company is unprofitable.

CEO

Junyou Ge (52 yo)

3.8yrs

Tenure

CN¥17,918,000

Compensation

Dr. Junyou Ge serves as an Executive Director of Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. since February 15, 2023 and its Chief Operation Officer since February 2021; General Manager since March 20...

Leadership Team

NamePositionTenureCompensationOwnership
Junyou Ge
President3.8yrsCN¥17.92mno data
Zejian Zhou
CFO & Joint Company Secretary2.3yrsno datano data
Yi Feng
Deputy GM4yrsno datano data
Xiangyang Tan
Deputy GM and Chief Scientific Officer of Biologics’ Research & Development3.4yrsno datano data
Xiaoping Jin
Deputy GM & Chief Medical Officer3.3yrsno datano data
Wai Sum Fung
Joint Company Secretary1.9yrsno datano data

3.3yrs

Average Tenure

49yo

Average Age

Experienced Management: 6990's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Junyou Ge
President2.8yrsCN¥17.92mno data
Qiang Zheng
Independent Non-Executive Director1.8yrsCN¥142.00kno data
Yuedong Li
Independent Non-Executive Director1.8yrsCN¥142.00kno data
Sichuan Liu
Non-Executive Director8.1yrsno datano data
Hao Feng
Non-Executive Director3.8yrsCN¥1.46mno data
Degui Lai
Non-Executive Directorless than a yearno datano data
Dongfang Li
Non Executive Director2.8yrsno datano data
Xuebo Zeng
Non-Executive Director2.4yrsno datano data
Jinping Jin
Independent Non-Executive Director1.8yrsCN¥142.00kno data
Gexin Liu
Non-Executive Chairman of the Board8.1yrsno datano data
Wenwei Tu
Independent Non-Executive Director1.8yrsCN¥142.00kno data
Yihong Liao
Chairperson of the Supervisory Committee2.8yrsno datano data

2.6yrs

Average Tenure

48.5yo

Average Age

Experienced Board: 6990's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 23:25
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is covered by 25 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited
Jingjing ZhangChina Merchants Securities Co. Ltd.